Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 100

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 100
---
 Consideration 
 Amount              |            |     | Percent |       |   |     | Average Price Per Ordinary 
 Share                      |       |
|:----------------------|:----|:-------|----------:|:----|:--------|------:|:--|:----|:--------------------|-----------:|:----|:--------|------:|:--|:----|:---------------------------|------:|
| Existing shareholders |     |        | 1,571,752 |     |         |       | % |     | $                   | 36,197,100 |     |         |       | % |     | $                          | 23.03 |
| New investors         |     |        |           |     |         |       | % |     | $                   |            |     |         |       | % |     | $                          |       |
| Total                 |     |        |           |     |         | 100.0 | % |     |                     |            |     | $       | 100.0 | % |     | $                          |       |

A $0.25 increase (decrease)
in the assumed initial public offering price of $ per Ordinary Share (the midpoint of the price range set
forth on the cover page of this prospectus) would increase (decrease) the total consideration paid by investors participating in this
offering, total consideration paid by all shareholders and the average price per share paid by all shareholders by approximately $ million,
$ million and $ , respectively, assuming that the number of Ordinary
Shares offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. Similarly, a 100,000 share increase (decrease) in the number
of Ordinary Shares offered by us, as set forth on the cover of this prospectus, would increase (decrease) the total consideration paid
by investors participating in this offering, total consideration paid by all shareholders and the average price per share paid by all
shareholders by approximately $ million, $ million and $ ,
respectively, assuming the assumed public offering price of $ per Ordinary Share remains the same,
and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

To the extent that outstanding
options are exercised, new options are issued or we issue additional Ordinary Shares in the future, there will be further dilution to
new